SuspendedPhase 1

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

Stopped: Lost funding.

United States120 participantsStarted 2021-10-05

Plain-language summary

This study will use brain Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) and an investigational radioactive drug called \[Zr-89\]oxine to track the location of white blood cells (also called leukocytes) in the body. PET/MRI will be used to visualize labeled white blood cells and determine if they enter the central nervous system in conditions associated with brain inflammation (also called neuroinflammation). By better understanding the role of neuroinflammation in fibromyalgia, chronic fatigue syndrome, and multiple sclerosis, the investigator hopes to be able to better diagnose and treat patients in the future.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.18 to 65 years of age 2.Healthy volunteer OR

Exclusion criteria

✕. Contraindication to MRI
✕. Pregnancy
✕. Lactation
✕. Individuals who are unable to participate in the imaging portion due to severity of their medical condition
✕. Chronic infectious disease (e.g. HIV, HCV)
✕. Viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation
✕. Diagnosis of cancer, including leukemia
✕. Blood or blood clotting disorder

What they're measuring

Regional brain distribution of radiolabeled white blood cells

Timeframe: 3 years

Trial details

NCT IDNCT03807973

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-10

View on ClinicalTrials.gov More Fibromyalgia trials